Hatorp V - Search Results

1

Pharmacokinetics of repaglinide in subjects with renal impairment.

Marbury TC, Ruckle JL, Hatorp V, Andersen MP, Nielsen KK, Huang WC, Strange P. Marbury TC, et al. Among authors: hatorp v. Clin Pharmacol Ther. 2000 Jan;67(1):7-15. doi: 10.1067/mcp.2000.103973. Clin Pharmacol Ther. 2000. PMID: 10668848 Clinical Trial.

2

Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.

Hatorp V, Hansen KT, Thomsen MS. Hatorp V, et al. J Clin Pharmacol. 2003 Jun;43(6):649-60. J Clin Pharmacol. 2003. PMID: 12817528 Clinical Trial.

3

Clinical pharmacokinetics and pharmacodynamics of repaglinide.

Hatorp V. Hatorp V. Clin Pharmacokinet. 2002;41(7):471-83. doi: 10.2165/00003088-200241070-00002. Clin Pharmacokinet. 2002. PMID: 12083976 Review.

4

Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment.

Schumacher S, Abbasi I, Weise D, Hatorp V, Sattler K, Sieber J, Hasslacher C. Schumacher S, et al. Among authors: hatorp v. Eur J Clin Pharmacol. 2001 May;57(2):147-52. doi: 10.1007/s002280100280. Eur J Clin Pharmacol. 2001. PMID: 11417447 Clinical Trial.

5

Drug interaction studies with repaglinide: repaglinide on digoxin or theophylline pharmacokinetics and cimetidine on repaglinide pharmacokinetics.

Hatorp V, Thomsen MS. Hatorp V, et al. J Clin Pharmacol. 2000 Feb;40(2):184-92. doi: 10.1177/00912700022008720. J Clin Pharmacol. 2000. PMID: 10664925

6

Single-dose pharmacokinetics of repaglinide in subjects with chronic liver disease.

Hatorp V, Walther KH, Christensen MS, Haug-Pihale G. Hatorp V, et al. J Clin Pharmacol. 2000 Feb;40(2):142-52. doi: 10.1177/00912700022008793. J Clin Pharmacol. 2000. PMID: 10664920 Clinical Trial.

7

Absorption, metabolism and excretion of a single oral dose of (14)C-repaglinide during repaglinide multiple dosing.

van Heiningen PN, Hatorp V, Kramer Nielsen K, Hansen KT, van Lier JJ, De Merbel NC, Oosterhuis B, Jonkman JH. van Heiningen PN, et al. Among authors: hatorp v. Eur J Clin Pharmacol. 1999 Sep;55(7):521-5. doi: 10.1007/s002280050667. Eur J Clin Pharmacol. 1999. PMID: 10501822 Clinical Trial.

8

Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes.

Damsbo P, Marbury TC, Hatorp V, Clauson P, Müller PG. Damsbo P, et al. Among authors: hatorp v. Diabetes Res Clin Pract. 1999 Aug;45(1):31-9. doi: 10.1016/s0168-8227(99)00057-1. Diabetes Res Clin Pract. 1999. PMID: 10499883 Clinical Trial.

9

Repaglinide pharmacokinetics in healthy young adult and elderly subjects.

Hatorp V, Huang WC, Strange P. Hatorp V, et al. Clin Ther. 1999 Apr;21(4):702-10. doi: 10.1016/S0149-2918(00)88321-6. Clin Ther. 1999. PMID: 10363735 Clinical Trial.

10

Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers.

Hatorp V, Oliver S, Su CA. Hatorp V, et al. Int J Clin Pharmacol Ther. 1998 Dec;36(12):636-41. Int J Clin Pharmacol Ther. 1998. PMID: 9877000 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results